The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis

被引：0
|
作者：
Giovannoni, G.
Comi, G.
Cook, S.
Beelke, M.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S245 / S245
页数：1
相关论文
共 50 条
  • [41] Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review
    Giovannoni, Gavin
    Mathews, Joela
    NEUROLOGY AND THERAPY, 2022, 11 (02) : 571 - 595
  • [42] Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
    Pierre Clavelou
    Giovanni Castelnovo
    Valérie Pourcher
    Jerome De Sèze
    Patrick Vermersch
    Ali-Frederic Ben-Amor
    Carine Savarin
    Gilles Defer
    Neurology and Therapy, 2023, 12 : 1457 - 1476
  • [43] Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets
    Gasperini, Claudio
    Ruggieri, Serena
    Pozzilli, Carlo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 391 - 399
  • [44] Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil W.
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Hicking, Christine
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (06) : 819 - 827
  • [45] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensen, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
  • [46] Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric, multinational study
    Adamec, I.
    Jakob, G. Brec
    Rajda, C.
    Drulovic, J.
    Radulovic, L.
    Kes, V. Basic
    Lazibat, I.
    Rimac, J.
    Cindric, I.
    Grzincic, T.
    Abicic, A.
    Barun, B.
    Gabelic, T.
    Gomezelj, S.
    Pekmezovic, T.
    Klivenyi, P.
    Skoric, M. Krbot
    Habek, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 180 - 180
  • [47] Cladribine TabletsIn Relapsing-Remitting Multiple Sclerosis
    Victoria J. Muir
    Greg L. Plosker
    CNS Drugs, 2011, 25 : 239 - 249
  • [48] An update on cladribine for relapsing-remitting multiple sclerosis
    Holmoy, Trygve
    Torkildsen, Oivind
    Myhr, Kjell-Morten
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (15) : 1627 - 1635
  • [49] CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis
    Miravalle, Augusto A.
    Katz, Joshua
    Robertson, Derrick
    Hayward, Brooke
    Harlow, Danielle E.
    Lebson, Lori A.
    Sloane, Jacob A.
    Bass, Ann D.
    Fox, Edward J.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (02) : 99 - 111
  • [50] Recommendations for the use of cladribine tablets in recurring multiple sclerosis
    Oreja-Guevara, Celia
    Garcia-Merino, Juan A.
    Saiz, Albert
    Rodriguez-Antiguedad, Alfredo
    Alvarez-Cermeno, Jose C.
    Estrada-Perez, Vicente
    Izquierdo, Guillermo
    Fernandez, Oscar
    REVISTA DE NEUROLOGIA, 2019, 69 : S1 - S9
12345